公司資料
Amarin Corporation 股價、新聞與催化劑
- 股票代碼:
- AMRN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Ireland and listed in the U
股票表現
14.01 USD (-0.43%)
收盤價
最後更新: 2026年8月17日
303M USD
市值
股價為何變動
As of Aug 17, 2026, AMRN closed down 0.43% at $14.01. No new same-company headline was identified in the current news window.
公司概覽
Cardiovascular Pharmaceutical Company
Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities.
Partnered International Model
Amarin shifted to a fully partnered international commercial strategy, including a long-term license and supply agreement with Recordati for Europe-focused commercialization across 59 countries. This model reduced operating expenses while allowing partners with local expertise to drive pricing, reimbursement, market access, and adoption.
U.S. Branded IPE Presence
In the United States, Amarin continues to maintain a leading branded IPE position despite generic competition. The company's U.S. IPE market share increased to 48% in the second quarter of 2026, while branded VASCEPA prescriptions rose year over year.
Strategic Position
Amarin is best understood as a focused cardiovascular company transitioning from direct global commercialization to a leaner partner-led international model. Its near-term performance depends on international volume growth, stable U.S. branded share, disciplined operating expenses, and positive cash flow generation.
未來催化劑
- Near-term commercialization progress in Singapore and South Korea.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。